Navigation Links
ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
Date:9/28/2008

LEUVEN, Belgium, September 29 /PRNewswire-FirstCall/ --

- Results Presented at World Stroke Congress in Vienna

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on novel therapies for eye disease, vascular disease and cancer, announces positive results from its MITI IV Phase II trial to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to acute stroke patients. The trial showed that microplasmin was generally well tolerated and also provided some interesting preliminary efficacy data. The overall results of the study were presented by Dr. Vincent Thijs on September 27 at a Late-Breaking Clinical Trial session at the World Stroke Congress.

The MITI IV (Microplasmin In Treatment of Ischemic stroke - IntraVenous) trial was a Phase II, multicentre, randomized, double-blinded, placebo-controlled, ascending-dose clinical trial evaluating the safety and preliminary efficacy of the intravenous administration of microplasmin in 40 patients, 4 to 12 hours after onset of acute ischemic stroke. The trial investigated three dose regimens of microplasmin (2, 3, and 4 mg/kg total dose) compared to placebo. Clinical outcomes were assessed at seven days and 30 days post-treatment, and at each of these visits neurological assessments were performed.

The study found that microplasmin was generally well tolerated with no evidence of increased bleeding risk; there were no systemic bleeding events reported and there was no evidence of increased rate of bleeding in general, in those patients that had been treated with microplasmin compared to those treated with placebo.

In addition, the study provided some interesting preliminary efficacy results. Approximately 25% of patients treated with microplasmin had reperfusion (restoration of blood flow) within eight hours of being treated, this compares with 10% of placebo-treated patients. Moreover, of the patients who had more severe va
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
3. Clinton Global Initiative Announces BDs Commitment to Biamba Marie Mutombo Hospital
4. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
5. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
6. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
7. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
8. Phosphagenics Announces Initiation of Phase 1 Clinical Trial in Humans for Its Transdermal Lidocaine
9. Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera
10. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
11. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) Needle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014  Aethlon Medical, Inc. ... definitive agreement to raise approximately $3.3 million at a ... made by one institutional healthcare focused investor. Each unit consists ... a common share purchase warrant. Each whole warrant entitles ... price of $0.30 for a period of five years ...
(Date:11/26/2014)...   Regulus Therapeutics Inc . (NASDAQ: ... development of innovative medicines targeting microRNAs, today announced that ... of Regulus, will present a company overview at the ... the New York Palace Hotel on Wednesday, December 3, ... webcast at the time of the presentation and can ...
(Date:11/26/2014)... -- BioScrip ® , Inc. (NASDAQ: BIOS ) announced today ... will present at the Bank of America Merrill Lynch 2014 Leveraged ... , , , Wednesday, December 3, 2014 , , , ... , , Location: , , , Boca Raton Resort and Club, ... BioScrip, Inc. is a leading national provider of ...
Breaking Medicine Technology:Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3
... -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: ... in the development, manufacturing, and marketing of branded and ... Mr. Hong Zhao, a highly regarded executive in the ... sales and marketing, effective February 12, 2011. ...
... Calif., Feb. 10, 2011 Renaissance Surgical Arts at Newport ... center in the Western United States to offer intraoperative radiotherapy ... in the TARGIT-A multicenter human clinical trial that demonstrated IORT ... with early breast cancer. IORT has the ...
Cached Medicine Technology:Simcere Pharmaceutical Group Appoints Industry Veteran Mr. Hong Zhao as Executive Vice President of Sales and Marketing 2Renaissance Surgical Arts at Newport Harbor Announces Single-Dose Radiation Treatment Alternative for Women with Early Breast Cancer 2Renaissance Surgical Arts at Newport Harbor Announces Single-Dose Radiation Treatment Alternative for Women with Early Breast Cancer 3
(Date:11/27/2014)... Ethane Web Technologies, which is an ... reputation management service. , The company has designed ... world of internet marketing and algorithms of major search ... Web Technologies does not work with the same strategy ... to reach a conclusion what will work for the ...
(Date:11/27/2014)... 2014 VeloReality Inc. President Gary ... Life Videos (RLVs) of world-famous velo courses for the company's ... as other popular indoor velo trainers. Two dozen additional Real ... the end of November -- in time for the ... of rides in the VeloReality collection to over sixty. , ...
(Date:11/27/2014)... November 27, 2014 Serious Buyer, Andrew ... 1969 Jimi Hendrix Tuscaloosa Memorial Coliseum concert posters. Between ... played at the University of Alabama. Jimi Hendrix started ... Hawley, “It started with Gary Weinberger who was a ... University Programs Council. The council was responsible for bringing ...
(Date:11/26/2014)... CA (PRWEB) November 26, 2014 Dr. ... treat themselves this holiday season! With Parsa Mohebi Hair ... 10% off of their next FUE procedure, making it ... , FUE—which stands for “Follicular Unit Extraction”—is an advanced ... over traditional “strip” Follicular Unit Transplantation (FUT). FUE, unlike ...
(Date:11/26/2014)... 27, 2014 Sweetdressy.com, the well-known wedding ... newest selection of cheap prom dresses for ladies worldwide. ... The prom dresses from Sweetdressy.com are very popular in ... the website of Sweetdressy.com now. , Sweetdressy.com believes ... that offering the best items and best services. The ...
Breaking Medicine News(10 mins):Health News:Ethane Web Technologies Announces Online Reputation Management Service 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 3Health News:Serious Buyer Announces His Search For Vintage 1969 Jimi Hendrix Tuscaloosa Memorial Coliseum Concert Posters 2Health News:FUE Special at Parsa Mohebi Hair Restoration This Holiday Season 2Health News:Cheap Prom Dresses For Ladies Introduced At SweetDressy.com 2
... May 8 (HealthDay News) -- People at risk for celiac ... they show no symptoms, a new study suggests. Celiac ... small intestine when the person consumes gluten, a protein found ... with the disease has grown rapidly in recent decades, but, ...
... , MONDAY, May 9 (HealthDay News) -- Some ... emotional reactions to everyday situations, a combination that appears ... a Massachusetts General Hospital study that included 83 participants ... deficient emotional self-regulation (DESR), 33 with neither condition -- ...
... of U.S. children taken to hospital emergency departments (EDs) for ... ease worried parents, concerns. Yet true traumatic brain injury is ... minor blunt head trauma, led by Children,s Hospital Boston and ... reduce the use of head CT by as much as ...
... UK,s betting shops are attracting a new type of ... terms of problem gambling, argues initial research findings funded ... Betting shops today are virtually unrecognisable compared to the ... Act. "Under the Act, the newly licensed betting offices ...
... -- (May 9, 2011) In the wild, mammals survive ... shadowy bushes. That ability translates to the human ... in an image of our messy and stuffed suitcases. We ... our car keys on that cluttered shelf next to the ...
... patient without common symptoms of celiac disease is accurately ... study from the Beth Israel Deaconess Medical Center in ... divided the cases of nearly 800 adult patients with ... per capita earnings. Some patients had complained of acute ...
Cached Medicine News:Health News:More People May Benefit From Going Gluten-Free 2Health News:ADHD With Poor Emotional Control Seems to Run in Families 2Health News:Large study finds CT scans are frequently unnecessary after head injury in children 2Health News:Large study finds CT scans are frequently unnecessary after head injury in children 3Health News:50 years on, UK betting shops lure new breed of punters 2Health News:The brain performs visual search near optimally 2
... Korchek Technologies CareChek ... employs barcode technology, Windows ... with integrated scanners (to ... at the bedside) and ...
... Korchek Technologies CareChek Rx ... barcode technology, Windows CE ... integrated scanners (to perform ... the bedside) and an ...
... care management tools that support the nursing ... vital signs and I&O information at the ... on-line flow sheets. This design supports compliance ... the hall, or at the nursing station, ...
For superior bar code scanning performance with maximum user comfort at a highly attractive price, the LS 4000i Scanner Series from Symbol Technologies establishes an award-winning standard of excell...
Medicine Products: